PR according to baseline characteristics: univariate analysis
| Baseline variable . | PR achieved n (%) . | Time to PR in days median (IQR) . | Unadjusted HR (CI) . |
|---|---|---|---|
| FVIII activity | |||
| <1 IU/dL (n = 47) | 36 (77) | 43 (28-64) | 0.54 (0.35-0.83)* |
| ≥1 IU/dL (n = 55) | 49 (89) | 24 (15-44) | |
| Inhibitor concentration | |||
| ≤20 BU/mL (n = 54) | 45 (83) | 26 (15-46) | 0.76 (0.50-1.16) |
| >20 BU/mL (n = 48) | 40 (83) | 35 (28-59) | |
| Gender | |||
| Female (n = 43) | 40 (93) | 35 (23-62) | 1.23 (0.80-1.89) |
| Male (n = 59) | 45 (76) | 28 (18-49) | |
| Age | |||
| ≤74 y (n = 53) | 48 (91) | 41 (23-64) | 0.83 (0.54-1.28) |
| >74 y (n = 49) | 37 (76) | 28 (18-36) | |
| WHO-PS | |||
| Good (≤2, n = 64) | 55 (86) | 32 (18-52) | 0.80 (0.51-1.25) |
| Poor (>2, n = 38) | 30 (79) | 30 (21-47) | |
| Underlying disorder | |||
| Autoimmunity (n = 20) | 19 (95) | 32 (23-51) | 1.31 (0.78-2.19) |
| Malignancy (n = 13) | 9 (69) | 21 (17-28) | 0.74 (0.37-1.48) |
| Pregnancy (n = 5) | 5 (100) | 50 (43-82) | 0.92 (0.38-1.28) |
| Baseline variable . | PR achieved n (%) . | Time to PR in days median (IQR) . | Unadjusted HR (CI) . |
|---|---|---|---|
| FVIII activity | |||
| <1 IU/dL (n = 47) | 36 (77) | 43 (28-64) | 0.54 (0.35-0.83)* |
| ≥1 IU/dL (n = 55) | 49 (89) | 24 (15-44) | |
| Inhibitor concentration | |||
| ≤20 BU/mL (n = 54) | 45 (83) | 26 (15-46) | 0.76 (0.50-1.16) |
| >20 BU/mL (n = 48) | 40 (83) | 35 (28-59) | |
| Gender | |||
| Female (n = 43) | 40 (93) | 35 (23-62) | 1.23 (0.80-1.89) |
| Male (n = 59) | 45 (76) | 28 (18-49) | |
| Age | |||
| ≤74 y (n = 53) | 48 (91) | 41 (23-64) | 0.83 (0.54-1.28) |
| >74 y (n = 49) | 37 (76) | 28 (18-36) | |
| WHO-PS | |||
| Good (≤2, n = 64) | 55 (86) | 32 (18-52) | 0.80 (0.51-1.25) |
| Poor (>2, n = 38) | 30 (79) | 30 (21-47) | |
| Underlying disorder | |||
| Autoimmunity (n = 20) | 19 (95) | 32 (23-51) | 1.31 (0.78-2.19) |
| Malignancy (n = 13) | 9 (69) | 21 (17-28) | 0.74 (0.37-1.48) |
| Pregnancy (n = 5) | 5 (100) | 50 (43-82) | 0.92 (0.38-1.28) |
P < .05 (statistical significance from univariate Cox regression analysis).